Black Diamond Therapeutics, Inc. (BDTX)

Market Cap	70.04M
Revenue (ttm)	n/a
Net Income (ttm)	-91.17M
Shares Out	36.48M
EPS (ttm)	-2.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,993
Open	1.81
Previous Close	1.85
Day's Range	1.80 - 1.88
52-Week Range	1.18 - 4.08
Beta	1.87
Analysts	Buy
Price Target	6.89 (+278.57%)
Earnings Date	May 10, 2023

About BDTX

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 30, 2020
• Employees: 86
• Stock Exchange: NASDAQ
• Ticker Symbol: BDTX

Analyst Forecast

According to 12 analysts, the average rating for BDTX stock is "Buy." The 12-month stock price forecast is $6.89, which is an increase of 278.57% from the latest price.

Price Target

$6.89

(278.57% upside)

Analyst Consensus: Buy